Wang Qing, Leclerc Julie, Bougeard Gaëlle, Olschwang Sylviane, Vasseur Stéphanie, Cassinari Kévin, Boidin Denis, Lefol Cédrick, Naïbo Pierre, Frébourg Thierry, Buisine Marie Pierre, Baert-Desurmont Stéphanie
Centre Léon Bérard, Laboratory of constitutional genetics for frequent cancers HCL-CLB, Lyon, France
Inserm UMR-S 1172, JPA Research Center, Lille University, and Department of Biochemistry and Molecular Biology, Lille University Hospital, Lille, France.
J Med Genet. 2020 Jul;57(7):487-499. doi: 10.1136/jmedgenet-2019-106256. Epub 2020 Jan 28.
Heterozygous germline variants are responsible for about 5% of Lynch syndrome (LS) but their prevalence is most likely underestimated because of complicated routine screening caused by highly homologous pseudogenes. Consequently, there is limited knowledge on the implication of the gene in LS.
We report 200 heterozygous variants identified in 195 French patients, including 112 unique variants classified as class-3/4/5.
Genomic rearrangements account for 18% of alterations. The c.137G>T variant was observed in 18% of the patients, but a founder effect could not be clearly identified by haplotype analysis. Among class-4/5 variant carriers, the median age at first tumour onset was 49 years with a predominance of colorectal (80%) and endometrial (8.1%) cancers. Seven patients developed colorectal cancers before the age of 30 with the youngest at the age of 21. Only 6.2% of class-4/5 carriers had a family history fulfilling Amsterdam I/II criteria among patients with available data. Tumours from variant carriers exhibited microsatellite instability (96%) and loss of PMS2 expression (76%), confirming the high predictive value of somatic analysis.
Our results provide further insight into the role of the gene in LS. While variants are mostly detected in families not fulfilling Amsterdam criteria, which supports their lower penetrance, they can nevertheless cause early-onset cancers, highlighting the variability of their penetrance.
杂合性种系变异约占林奇综合征(LS)的5%,但由于高度同源假基因导致常规筛查复杂,其患病率很可能被低估。因此,关于该基因在LS中的影响的了解有限。
我们报告了在195名法国患者中鉴定出的200个杂合变异,其中包括112个被分类为3/4/5类的独特变异。
基因组重排占改变的18%。18%的患者中观察到c.137G>T变异,但通过单倍型分析无法明确鉴定出奠基者效应。在4/5类变异携带者中,首次发生肿瘤的中位年龄为49岁,以结直肠癌(80%)和子宫内膜癌(8.1%)为主。7名患者在30岁之前发生结直肠癌,最年轻的为21岁。在有可用数据的患者中,只有6.2%的4/5类携带者有符合阿姆斯特丹I/II标准的家族史。变异携带者的肿瘤表现出微卫星不稳定性(96%)和PMS2表达缺失(76%),证实了体细胞分析的高预测价值。
我们的结果进一步深入了解了该基因在LS中的作用。虽然变异大多在不符合阿姆斯特丹标准的家族中被检测到,这支持了它们较低的外显率,但它们仍可导致早发性癌症,突出了其外显率的变异性。